在接受直接口服抗凝剂的患者中,提取后出血
Min-Ji Kim1, Moon-Key Kim2, Sang-Hoon Kang2
1Department of Oral and Maxillofacial Surgery, Yonsei University College of Dentistry, Seoul, Korea.
概括
在拔牙过程中继续服用直接口服抗凝剂 (DOACs),不会增加拔牙后出血的风险. 这一发现支持对接受牙切除牙的DOAC患者的安全管理.
科学领域:
- 口腔和牙面部外科手术
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 直接口服抗凝剂 (DOAC) 是广泛用于血栓预防的药物.
- 管理需要牙科手术的DOAC患者需要了解出血风险.
研究的目的:
- 评估持续使用直接口服抗凝剂 (DOAC) 与抽取后出血之间的关联.
- 在接受DOAC治疗期间接受牙切割患者的出血风险的量化.
主要方法:
- 一项涉及293名患者的研究,其中414名患者接受了牙拔除.
- 患者被分为两组:那些继续服用DOAC的人和那些在提取之前停止服用DOAC的人.
- 记录出血并发症,并在各组之间进行比较.
主要成果:
- 抽取后出血发生在6.9%的患者 (12在293人中).
- 继续服用DOACs的12名患者 (8.5%) 经历出血,而在停止服用DOACs的组中没有任何患者.
- 两组之间没有观察到出血并发症的统计学上显著差异 (P=0.122).
结论:
- 在拔牙期间继续DOAC治疗与拔牙后出血倾向的增加无关.
- 这些发现与之前的研究一致,表明当前的DOAC可以在牙科手术期间安全管理.
相关概念视频
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
654
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
654
Disorders of Hemostasis
754
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
754
Extrinsic and Intrinsic Pathways of Hemostasis
6.5K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
6.5K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
499
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
499
Introduction to Hemostasis
6.7K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
6.7K


